Changes of intestinal bacterial microbiota in coronary heart disease complicated with nonalcoholic fatty liver disease

• Published in: BMC genomics 2019-11, Vol.20 (1), p.862-862, Article 862
• Main Authors: Zhang, Yiwen, Xu, Jun, Wang, Xuemei, Ren, Xinhua, Liu, Yulan
• Format: Article
• Language: English
• Subjects: Aged; Bacteria - classification; Bacteria - genetics; Biodiversity; Biomarkers; Cardiac patients; Cardiovascular diseases; Coronary Disease - complications; Coronary Disease - diagnosis; Coronary Disease - metabolism; Coronary Disease - mortality; Coronary heart disease; Development and progression; Disease Susceptibility; DNA sequencing; Fatty liver; Feces - microbiology; Female; Gastrointestinal Microbiome; Heart; Heart diseases; Humans; Intestinal microbiota; Liver diseases; Male; Medical research; Microbiota (Symbiotic organisms); Middle Aged; Non-alcoholic fatty liver disease; Non-alcoholic Fatty Liver Disease - complications; Non-alcoholic Fatty Liver Disease - diagnosis; Non-alcoholic Fatty Liver Disease - metabolism; Organ Specificity; Purines; RNA; Severity of Illness Index; Somatotropin; Triglycerides; Uric acid
• ISSN: 1471-2164; 1471-2164
• DOI: 10.1186/s12864-019-6251-7

Previous study reported that patients who suffered coronary heart disease (CHD) complicated with non-alcoholic fatty liver disease (NAFLD) had worse cardiac function and clinical outcomes than patients with CHD only. Notably, the mechanism is still unclear. This study aimed to investigate the changes and roles of intestinal bacterial microbiota in CHD-NAFLD patients. People were recruited and divided into three groups, including CHD patients (without NAFLD), CHD-NAFLD patients and healthy controls (HCs). Each group contained 24 people. Fecal samples and clinical information were carefully collected. The Illumina sequencing of 16S rRNA was applied to profile the overall structure of the fecal bacterial microbiota and the characteristics of the bacterial microbiota based on the Operational Taxonomic Units. In clinical information, the CHD-NAFLD patients showed an increase in BMI, uric acid and triglyceride. There was a significant reduction in the abundance of Parabacteroides and Collinsella in overall CHD patients (including CHD-NAFLD and CHD patients). The intestinal bacterial microbiota in CHD-NAFLD patients showed an increase in the abundance of Copococcus and Veillonella, and a reduction in the abundance of Parabacteroides, Bacteroides fragilis, Ruminococcus gnavus, Bacteroides dorei, and Bifidobacterium longum subsp infantis. Among them, the abundance of Ruminococcus gnavus and Bacteroides dorei was significantly lower than that in CHD patients. Additionally, BMI positively correlated with the abundance of Copococcus and negatively correlated with the abundance of Bifidobacterium longum subsp infantis. The abundance of Veillonella positively correlated with AST. The abundance of Bacteroides dorei negatively correlated with ALT and AST. It indicates that the abundance of intestinal microbiota was related to the changes in clinical indexes. Changes of intestinal bacterial microbiota in CHD-NAFLD patients may be important factors affecting the degree of metabolic disorder, which may be one of the important reasons for the worse clinical outcome and disease progression in CHD-NAFLD patients than in CHD patients.